3843 GA Harderwijk (the Netherlands), nl
+31 (88) 1221-000
Biomedical big data analysis company Genalice receives a multi-million euro capital investment
Lead investor Zaheer Sardar, comments: "With the successful validation of GENALICE MAP, we really have found a major game changer in the field of genomics. Big data analysis is a critical problem in this area, and we are delighted to back a company that has developed an innovative product resulting in greater accuracy, improved speed and lower costs. Our investment will contribute to accelerating this exciting phase of the GENALICE story."
During a 24-hour webcast in December 2013, GENALICE showcased MAP's robustness and spectacular performance. The product is up to 100 times faster than conventional tools on commodity hardware. Hans Karten, GENALICE's CEO/CTO, adds: "Our MAP product is based on several technical innovations and is a leap forward for researchers demanding high-quality and cost-effective DNA data processing. With the advent of the $1,000 genome, GENALICE provides a correspondingly low-cost data processing and storage solution, available immediately. We view this as a very positive outcome for users of Illumina X Ten sequencing machines, as GENALICE provides a highly efficient IT solution to deal with massive data-file production. For example, GENALICE's XS model is capable of processing data at a speed that can exceed the maximum throughput of an ultra-high-throughput sequencer; the Illumina X Ten farm, which can process 18,000 full genomes per year. But our sequence alignment and variant calling solution offers so much more than ultra-fast processing of NGS data. GENALICE MAP truly raises NGS data processing and analysis to a new level of performance, with world-beating accuracy, significant storage cost reductions, full compatibility with other pipelines and excellent user-friendliness. GENALICE provides a comprehensive solution to the analysis speed and file-size problem in a single product, so researchers can move straight to the science and concentrate on solving genetic problems."
GENALICE MAP is already being evaluated and installed by high-volume NGS centers, institutes and companies around the world. Karten states: "We have been greatly encouraged by real-world results which are proving to be the breakthrough that our models had forecast. It is no surprise that some of the early Illumina HiSeq X Ten customers are already users of MAP. We welcome further enquiries from organizations engaged in genomic data analysis so they can see the results for themselves, in their own environment and under their own conditions. We would be prepared to discuss evaluation kits for qualified prospects, as we believe the solution will quickly prove its value."
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.